DDInter1867 DDInter640
A phenothiazine used as an antipsychotic agent and as an antiemetic.
Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and secretion. Mutations in this gene, most frequently the V600E mutation, are the most commonly identified cancer-causing mutations in melanoma, and have been isolated in various other cancers as well, including non-Hodgkin lymphoma, colorectal cancer, thyroid carcinoma, non-small cell lung carcinoma, hairy cell leukemia and adenocarcinoma of the lung. On June 27, 2018, the Food and Drug Administration approved encorafenib and [binimetinib] (BRAFTOVI and MEKTOVI, Array BioPharma Inc.) in combination for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.
Triflupromazine {u} (Compound) resembles {v} (Compound) Chlorpromazine
Chlorpromazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Encorafenib
Triflupromazine {u} (Compound) resembles {v} (Compound) Thioridazine
Thioridazine {u} may lead to a major life threatening interaction when taken with {v} Encorafenib
Triflupromazine {u} (Compound) resembles {v} (Compound) Chlorpromazine
Chlorpromazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Encorafenib
Triflupromazine {u} (Compound) resembles {v} (Compound) Clomipramine
Clomipramine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Encorafenib
Triflupromazine {u} (Compound) resembles {v} (Compound) Pipotiazine
Pipotiazine {u} (Compound) resembles {v} (Compound) Methotrimeprazine
Methotrimeprazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Encorafenib
Triflupromazine {u} (Compound) resembles {v} (Compound) Chlorpromazine
Chlorpromazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mineral oil
Mineral oil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Encorafenib
Triflupromazine {u} (Compound) resembles {v} (Compound) Clomipramine
Clomipramine {u} (Compound) resembles {v} (Compound) Chlorpromazine
Chlorpromazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Encorafenib
Triflupromazine {u} (Compound) resembles {v} (Compound) Promethazine
Promethazine {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Chlorpromazine
Chlorpromazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Encorafenib
Triflupromazine {u} (Compound) resembles {v} (Compound) Desipramine
Desipramine {u} (Compound) resembles {v} (Compound) Promazine
Promazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Encorafenib
Triflupromazine {u} (Compound) resembles {v} (Compound) Chlorpromazine
Chlorpromazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Troglitazone
Troglitazone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Encorafenib
Triflupromazine (Compound) resembles Chlorpromazine (Compound) and Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Triflupromazine (Compound) resembles Thioridazine (Compound) and Thioridazine may lead to a major life threatening interaction when taken with Encorafenib
Triflupromazine (Compound) resembles Chlorpromazine (Compound) and Chlorpromazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Encorafenib
Triflupromazine (Compound) resembles Clomipramine (Compound) and Clomipramine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Encorafenib
Triflupromazine (Compound) resembles Pipotiazine (Compound) and Pipotiazine (Compound) resembles Methotrimeprazine (Compound) and Methotrimeprazine may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Triflupromazine (Compound) resembles Chlorpromazine (Compound) and Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil and Mineral oil may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Triflupromazine (Compound) resembles Clomipramine (Compound) and Clomipramine (Compound) resembles Chlorpromazine (Compound) and Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Triflupromazine (Compound) resembles Promethazine (Compound) and Promethazine (Compound) resembles Chlorpromazine (Compound) and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpromazine and Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Triflupromazine (Compound) resembles Desipramine (Compound) and Desipramine (Compound) resembles Promazine (Compound) and Promazine may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Triflupromazine (Compound) resembles Chlorpromazine (Compound) and Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib